WallStSmart

Boston Scientific Corp (BSX)vsFox Corp Class B (FOX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 21% more annual revenue ($20.07B vs $16.58B). BSX leads profitability with a 14.4% profit margin vs 11.4%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

FOX

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 7.0Value: 4.7Quality: 8.0
Piotroski: 5/9Altman Z: 2.44
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued
FOXSignificantly Overvalued (-95.5%)

Margin of Safety

-95.5%

Fair Value

$28.36

Current Price

$52.35

$23.99 premium

UndervaluedFair: $28.36Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

FOX2 strengths · Avg: 8.0/10
P/E RatioValuation
12.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

FOX4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
2.0%4/10

2.0% revenue growth

PEG RatioValuation
11.992/10

Expensive relative to growth rate

EPS GrowthGrowth
-35.8%2/10

Earnings declined 35.8%

Free Cash FlowQuality
$-773.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : FOX

The strongest argument for FOX centers on P/E Ratio, Price/Book.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : FOX

The primary concerns for FOX are Revenue Growth, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

BSX profiles as a growth stock while FOX is a value play — different risk/reward profiles.

BSX carries more volatility with a beta of 0.70 — expect wider price swings.

BSX is growing revenue faster at 15.9% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 51/100) and 15.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Fox Corp Class B

COMMUNICATION SERVICES · ENTERTAINMENT · USA

Fox Corporation is an American mass media company headquartered in New York City.

Want to dig deeper into these stocks?